Search
Results: 29
Refractory lupus nephritis
Andreas Kronbichler, Biljana Brezina, Philipp Gauckler, Luis F Quintana, David RW Jayne
May 13, 2019
Refractory lupus nephritis indicates an inadequate response to lupus nephritis therapy. It implies persisting or worsening disease activity despite therapy, but the definition is complicated by the parameters of response...
Standardized Index of Shape (DCE-MRI) and Standardized Uptake Value (PET/CT)
Antonella Petrillo, Roberta Fusco, Mario Petrillo, Vincenza Granata, Paolo Delrio, Francesco Bianco, Biagio Pecori, Gerardo Botti, Fabiana Tatangelo, Corradina Caracò, Luigi Aloj, Antonio Avallone, Secondo Lastoria
May 03, 2019
PURPOSE: To investigate dynamic contrast enhanced-MRI (DCE-MRI) in the preoperative chemo-radiotherapy (CRT) assessment for locally advanced rectal cancer (LARC) compared to18F-fluorodeoxyglucose positron emission...
DCE-MRI and FDG-PET/CT neoadjuvant chemo-radiotherapy rectal cancer treatment response assessment Adult Aged Area Under Curve Chemoradiotherapy Adjuvant Contrast Media Digestive System Surgical Procedures Female Fluorodeoxyglucose F18 Humans Magnetic Resonance Imaging Magnetite Nanoparticles Male Middle Aged Neoadjuvant Therapy Perfusion Imaging Positron Emission Tomography Computed Tomography Predictive Value of Tests ROC Curve Radiopharmaceuticals Rectal Neoplasms Regional Blood Flow Remission Induction Reproducibility of Results Siloxanes Treatment Outcome
Brief Report
Federica Maritati, Roberta Fenoglio, Evangeline Pillebout, Giacomo Emmi, Maria L Urban, Rossana Rocco, Maria Nicastro, Monia Incerti, Matteo Goldoni, Giorgio Trivioli, Elena Silvestri, Aladdin J Mohammad, David Jayne, Per Eriksson, Mårten Segelmark, Pavel Novikov, Helen Harris, Dario Roccatello, Augusto Vaglio
Feb 26, 2020
OBJECTIVE: Adult-onset IgA vasculitis (Henoch-Schönlein) (IgAV) is a rare systemic vasculitis characterized by IgA1-dominant deposits. The treatment of adult-onset IgAV is controversial and is based on the combination of...
Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach.
Megan RW Barber, John G Hanly, Li Su, Murray B Urowitz, Yvan St Pierre, Juanita Romero-Diaz, Caroline Gordon, Sang-Cheol Bae, Sasha Bernatsky, Daniel J Wallace, Joan T Merrill, David A Isenberg, Anisur Rahman, Ellen M Ginzler, Michelle Petri, Ian N Bruce, Mary A Dooley, Paul R Fortin, Dafna D Gladman, Jorge Sanchez-Guerrero, Kristjan Steinsson, Rosalind Ramsey-Goldman, Munther A Khamashta, Cynthia Aranow, Meggan Mackay, Graciela S Alarcón, Susan Manzi, Ola Nived, Andreas Jönsen, Asad A Zoma, Ronald F van Vollenhoven, Manuel Ramos-Casals, Guillermo Ruiz-Irastorza, S Sam Lim, Kenneth C Kalunian, Murat Inanc, Diane L Kamen, Christine A Peschken, Søren Jacobsen, Anca Askanase, Vernon Farewell, Thomas Stoll, Jill Buyon, Ann E Clarke
Oct 01, 2019
OBJECTIVE: There is a paucity of data regarding health care costs associated with damage accrual in systemic lupus erythematosus. The present study was undertaken to describe costs associated with damage states across the...
Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
Alexandre Karras, Christian Pagnoux, Marion Haubitz, Kirsten de Groot, Xavier Puechal, Jan Willem Cohen Tervaert, Mårten Segelmark, Loic Guillevin, David Jayne, European Vasculitis Society
Feb 27, 2020
OBJECTIVES: A prospective randomised trial to compare two different durations of maintenance immunosuppressive therapy for the prevention of relapse in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV)....
ANCA Azathioprine maintenance therapy Relapse Vasculitis Adult Aged Anti-Inflammatory Agents Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antibodies Antineutrophil Cytoplasmic Azathioprine Creatinine cyclophosphamide Female Glomerular Filtration Rate Humans Immunosuppressive Agents Kidney Failure Chronic Maintenance Chemotherapy Male Middle Aged Prednisolone Prospective Studies Remission Induction Secondary Prevention Survival Rate Time Factors
Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
David Jayne, Daniel Blockmans, Raashid Luqmani, Sergey Moiseev, Beulah Ji, Yulia Green, Leanne Hall, David Roth, Robert B Henderson, Peter A Merkel, BREVAS Study Collaborators
Jun 28, 2019
OBJECTIVE: To evaluate the safety and efficacy of belimumab as adjunctive therapy to maintain remission in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). METHODS: In this multicenter, double-blind...
Adult Aged Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antibodies Antineutrophil Cytoplasmic Antibodies Monoclonal Humanized Azathioprine B-Lymphocytes cyclophosphamide Double-Blind Method Drug Therapy Combination Female Glucocorticoids Humans Immunoglobulins Immunosuppressive Agents Infections Maintenance Chemotherapy Male Middle Aged Remission Induction Rituximab Treatment Outcome
Alemtuzumab for refractory primary systemic vasculitis-a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE).
Seerapani Gopaluni, Rona Smith, Donna Goymer, Hugh Cahill, Elizabeth Broadhurst, Elizabeth Wallin, Mark McClure, Afzal Chaudhry, David Jayne
Apr 01, 2022
BACKGROUND: Primary systemic vasculitis (PSV) is a heterogeneous group of autoimmune conditions. There is an unmet need for alternative therapies that lead to sustained remission in patients with refractory disease. Alemtuzumab...
Symptom remission at 12-weeks strongly predicts long-term recovery from the first episode of psychosis.
Paola Dazzan, Julia M Lappin, Margaret Heslin, Kim Donoghue, Ben Lomas, Uli Reininghaus, Adanna Onyejiaka, Tim Croudace, Peter B Jones, Robin M Murray, Paul Fearon, Gillian A Doody, Craig Morgan
Nov 22, 2019
clinical outcome Functional outcome Psychosis Remission Schizophrenia Activities of Daily Living Adult Bipolar Disorder Female Follow-Up Studies Humans Logistic Models Male Outcome Assessment Health Care Psychiatric Status Rating Scales Psychotic Disorders Remission Induction Schizophrenia Schizophrenic Psychology United Kingdom Young Adult
COVID-19 and ANCA-associated vasculitis
Annette Bruchfeld, Andreas Kronbichler, Federico Alberici, Fernando C Fervenza, David RW Jayne, Mårten Segelmark, Vladimir Tesar, Wladimir M Szpirt
Nov 17, 2021
COVID-19 and ANCA-associated vasculitis - recommendations for vaccine preparedness and the use of rituximab.
Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial)
Naomi H Martin, Fowzia Ibrahim, Brian Tom, James Galloway, Allan Wailoo, Jonathan Tosh, Heidi Lempp, Louise Prothero, Sofia Georgopoulou, Jackie Sturt, David L Scott, TITRATE Programme Investigators
Aug 03, 2018
intensive treatment Intermediate disease activity randomised controlled trial rheumatoid arthritis Treating to target Tumour necrosis factor inhibitors Antirheumatic Agents Arthritis Rheumatoid Blood Sedimentation Clinical Protocols Cost-Benefit Analysis Disability Evaluation Drug Costs England Humans Motivational interviewing Patient-Centered Care Quality of life Remission Induction Research Design Severity of Illness Index Surveys and Questionnaires Time Factors Treatment Outcome
Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse.
Matthew David Morgan, Matthew Szeto, Michael Walsh, David Jayne, Kerstin Westman, Niels Rasmussen, Thomas F Hiemstra, Oliver Flossmann, Annelies Berden, Peter Höglund, Lorraine Harper, European Vasculitis Society
Jun 08, 2017
ANCA ANCA-associated vasculitis clinical trial prognostic factors Relapse Treatment Vasculitis Adult Aged Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antibodies Antineutrophil Cytoplasmic cyclophosphamide Disease-Free Survival Female Humans Immunosuppressive Agents Maintenance Chemotherapy Male Middle Aged Outcome Assessment Health Care Proportional Hazards Models Randomized Controlled Trials as Topic Recurrence Remission Induction Retrospective Studies Risk Factors
Inducing remission of Type 2 diabetes in the Caribbean
K Bynoe, N Unwin, C Taylor, MM Murphy, L Bartholomew, A Greenidge, M Abed, S Jeyaseelan, C Cobelli, C Dalla Man, R Taylor
Aug 09, 2019
AIM: In a high proportion of people with recently diagnosed Type 2 diabetes, a short (2-3-month) low-calorie diet is able to restore normal glucose and insulin metabolism. The aim of this study was to determine the feasibility...
Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Seerapani Gopaluni, Oliver Flossmann, Mark A Little, Paul O'Hara, Pirow Bekker, David Jayne, European Vasculitis Society
Dec 13, 2018
OBJECTIVE: The treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) aims to suppress disease activity and prevent subsequent disease flare. This study sought to explore the association of early...
Adult Age Factors Aged Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Female Glomerular Filtration Rate Humans Immunosuppressive Agents Kidney Failure Chronic Male Middle Aged Mortality Plasma Exchange Prognosis Proportional Hazards Models Recurrence Remission Induction Severity of Illness Index
Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis.
Stephen P McAdoo, Nicholas Medjeral-Thomas, Seerapani Gopaluni, Anisha Tanna, Nicholas Mansfield, Jack Galliford, Megan Griffith, Jeremy Levy, Thomas D Cairns, David Jayne, Alan D Salama, Charles D Pusey
Sep 08, 2018
Background. Current guidelines advise that rituximab or cyclophosphamide should be used for the treatment of organthreatening disease in anti-neutrophil cytoplasm antibody
(ANCA)-associated vasculitis (AAV), although few...
Adolescent Adult Aged Aged 80 and over Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antineoplastic Combined Chemotherapy Protocols Azathioprine Case-Control Studies Cohort Studies cyclophosphamide Disease Progression Female Follow-Up Studies Glomerular Filtration Rate Humans Kidney Diseases Kidney Failure Chronic Male Middle Aged Prognosis Remission Induction Rituximab Survival Rate Young Adult
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa
Paul A Brogan, Barbara Arch, Helen Hickey, Jordi Anton, Este Iglesias, Eileen Baildam, Kamran Mahmood, Gavin Cleary, Elena Moraitis, Charalampia Papadopoulou, Michael W Beresford, Phil Riley, Selcan Demir, Seza Ozen, Giovanna Culeddu, Dyfrig A Hughes, Pavla Dolezalova, Lisa V Hampson, John Whitehead, David Jayne, Nicola Ruperto, Catrin Tudur-Smith, Despina Eleftheriou
Apr 19, 2021
OBJECTIVE: Cyclophosphamide (CYC) is used in clinical practice off-label for the induction of remission in childhood polyarteritis nodosa (PAN). Mycophenolate mofetil (MMF) might offer a less toxic alternative. This study was...
PRedicting Outcomes For Crohn's dIsease using a moLecular biomarkEr (PROFILE)
Miles Parkes, Nurulamin M Noor, Francis Dowling, Harvey Leung, Simon Bond, Lynne Whitehead, Sara Upponi, Paul Kinnon, Andrew P Sandham, Paul A Lyons, Eoin F McKinney, Kenneth GC Smith, James C Lee
Dec 11, 2018
2021 DORIS definition of remission in SLE
Ronald F van Vollenhoven, George Bertsias, Andrea Doria, David Isenberg, Eric Morand, Michelle A Petri, Bernardo A Pons-Estel, Anisur Rahman, Manuel Francisco Ugarte-Gil, Alexandre Voskuyl, Laurent Arnaud, Ian N Bruce, Ricard Cervera, Nathalie Costedoat-Chalumeau, Caroline Gordon, Frédéric A Houssiau, Marta Mosca, Matthias Schneider, Michael M Ward, Graciela Alarcon, Martin Aringer, Anka Askenase, Sang-Cheol Bae, Hendrika Bootsma, Dimitrios T Boumpas, Hermine Brunner, Ann Elaine Clarke, Cindy Coney, László Czirják, Thomas Dörner, Raquel Faria, Rebecca Fischer, Ruth Fritsch-Stork, Murat Inanc, Søren Jacobsen, David Jayne, Annegret Kuhn, Bernadette van Leeuw, Maarten Limper, Xavier Mariette, Sandra Navarra, Mandana Nikpour, Marzena Helena Olesinska, Guillermo Pons-Estel, Juanita Romero-Diaz, Blanca Rubio, Yehuda Schoenfeld, Eloisa Bonfá, Josef Smolen, YK Onno Teng, Angela Tincani, Michel Tsang-A-Sjoe, Carlos Vasconcelos, Anne Voss, Victoria P Werth, Elena Zakharhova, Cynthia Aranow
Feb 14, 2022
OBJECTIVE: To achieve consensus on a definition of remission in SLE (DORIS). BACKGROUND: Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an...
Moderate weight change following diabetes diagnosis and 10 year incidence of cardiovascular disease and mortality.
Jean Strelitz, Amy L Ahern, Gráinne H Long, Matthew JL Hare, Greg Irving, Clare E Boothby, Nicholas J Wareham, Simon J Griffin
May 02, 2019
cardiovascular disease Diabetes EPIDEMIOLOGY Weight Loss Adult Body Weight Cardiovascular Diseases Cluster Analysis Denmark Diabetes Complications Diabetes mellitus Type 2 England Follow-Up Studies Humans Incidence Netherlands Observational Studies as Topic Pragmatic Clinical Trials as Topic Proportional Hazards Models Regression Analysis Remission Induction Risk Factors Social Class Treatment Outcome Weight Gain Weight Loss
Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM)
Seerapani Gopaluni, Rona M Smith, Michelle Lewin, Carol A McAlear, Kim Mynard, Rachel B Jones, Ulrich Specks, Peter A Merkel, David RW Jayne, RITAZAREM Investigators
May 05, 2017
BACKGROUND: Rituximab is effective as therapy for induction of remission in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and subsequent relapse rates...
ANCA-associated vasculitis Azathioprine RITAZAREM Randomized clinical trial Rituximab Administration Intravenous Administration Oral Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Australia Azathioprine Clinical Protocols Europe Glucocorticoids Humans Immunosuppressive Agents Japan Maintenance Chemotherapy New Zealand Recurrence Remission Induction Research Design Rituximab Time Factors Treatment Outcome
Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis
Duvuru Geetha, Cees Kallenberg, John H Stone, Alan D Salama, Gerald B Appel, George Duna, Paul Brunetta, David Jayne
Nov 24, 2020
Granulomatosis with polyangiitis and microscopic polyangiitis are anti-neutrophil cytoplasmic antibody-associated vasculitides (AAVs) that are prone to cycles of remission and relapse. The introduction of cytotoxic therapy has...
Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis.
Ruth J Pepper, Sally Hamour, Konstantia-Maria Chavele, Sarah K Todd, Niels Rasmussen, Shaun Flint, Paul A Lyons, Kenneth GC Smith, Charles D Pusey, H Terence Cook, Alan D Salama
Nov 29, 2018
Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) commonly results in glomerulonephritis, in which neutrophils and monocytes have important roles. The heterodimer calprotectin (S100A8/S100A9, mrp8/14) is a...
Adolescent Adult Aged Aged 80 and over Analysis of Variance Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Biomarkers Biopsy Calgranulin A Calgranulin B Case-Control Studies Disease Progression Enzyme-Linked Immunosorbent Assay Female Flow Cytometry glomerulonephritis Humans Immunohistochemistry Inflammation Mediators Kidney Leukocytes Male Middle Aged Neutrophils Predictive Value of Tests Prognosis Protein Multimerization Remission Induction Young Adult
Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.
Mark E McClure, James Wason, Seerapani Gopaluni, Joanna Tieu, Rona M Smith, David R Jayne, Rachel B Jones
Apr 12, 2019
Avacopan for the Treatment of ANCA-Associated Vasculitis.
BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. METHODS: In this randomized, controlled trial, we assigned patients with...
Administration Oral Aniline Compounds Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Azathioprine cyclophosphamide Double-Blind Method Drug Therapy Combination Female Glucocorticoids Humans Immunosuppressive Agents Kaplan-Meier Estimate Male Middle Aged Nipecotic Acids prednisone Receptor Anaphylatoxin C5a Recurrence Remission Induction Rituximab
|
|< |
< |
1 |